Key clinical point: Overweight and underweight RA patients were more likely than normal weight patients to discontinue TNFi treatment.
Major finding: TNFi survival hazard ratios for RA patients with class II obesity, class III obesity, and underweight were 1.28, 1.67, and 1.30, respectively.
Study details: The data come from an observational study of 5,230 adults with rheumatoid arthritis from the METEOR registry.
Disclosures: The study was supported by a research grant from Bristol-Myers Squibb. One author reported being a speaker for Roche and Bristol-Myers Squibb.
Bergstra SA et al. RMD Open. 2020;6:e001203. doi: 10.1136/rmdopen-2020- 001203.